| Carlos Velazquez, | |
|
17212 N Rosa Dr, Maricopa, AZ 85138-1835 | |
| (309) 299-0118 | |
| Not Available |
| Full Name | Carlos Velazquez |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 10 Years |
| Location | 17212 N Rosa Dr, Maricopa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295124485 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 041368600 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Boswell Medical Center | Sun city, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greater Anesthesia Solutions | 9234357906 | 155 |
News Archive
Combating malaria and other so-called vector diseases with chemical controls is increasingly ineffective, besides being hazardous for humans and the environment. These chemical controls must therefore be eliminated. In order to combat the diseases that insects and ticks transmit, all possible strategies must be united.
The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.
Researchers at the Case Western Reserve University School of Medicine, with colleagues from the John P. Hussman Institute for Human Genomics at the University of Miami, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, at Columbia University, and Wake Forest University School of Medicine will study the genomics of Alzheimer's disease (AD) in people with African heritage throughout the United States.
CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.
Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.
› Verified 2 days ago
| Entity Name | Greater Anesthesia Solutions |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124430244 PECOS PAC ID: 9234357906 Enrollment ID: O20140822000525 |
News Archive
Combating malaria and other so-called vector diseases with chemical controls is increasingly ineffective, besides being hazardous for humans and the environment. These chemical controls must therefore be eliminated. In order to combat the diseases that insects and ticks transmit, all possible strategies must be united.
The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.
Researchers at the Case Western Reserve University School of Medicine, with colleagues from the John P. Hussman Institute for Human Genomics at the University of Miami, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, at Columbia University, and Wake Forest University School of Medicine will study the genomics of Alzheimer's disease (AD) in people with African heritage throughout the United States.
CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.
Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.
› Verified 2 days ago
| Entity Name | Anesthesia Partners & Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336530997 PECOS PAC ID: 9931429198 Enrollment ID: O20150529000706 |
News Archive
Combating malaria and other so-called vector diseases with chemical controls is increasingly ineffective, besides being hazardous for humans and the environment. These chemical controls must therefore be eliminated. In order to combat the diseases that insects and ticks transmit, all possible strategies must be united.
The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.
Researchers at the Case Western Reserve University School of Medicine, with colleagues from the John P. Hussman Institute for Human Genomics at the University of Miami, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, at Columbia University, and Wake Forest University School of Medicine will study the genomics of Alzheimer's disease (AD) in people with African heritage throughout the United States.
CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.
Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.
› Verified 2 days ago
| Entity Name | Anesthesia Partners Of Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619452901 PECOS PAC ID: 8628317179 Enrollment ID: O20190228001927 |
News Archive
Combating malaria and other so-called vector diseases with chemical controls is increasingly ineffective, besides being hazardous for humans and the environment. These chemical controls must therefore be eliminated. In order to combat the diseases that insects and ticks transmit, all possible strategies must be united.
The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.
Researchers at the Case Western Reserve University School of Medicine, with colleagues from the John P. Hussman Institute for Human Genomics at the University of Miami, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, at Columbia University, and Wake Forest University School of Medicine will study the genomics of Alzheimer's disease (AD) in people with African heritage throughout the United States.
CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.
Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carlos Velazquez, 17212 N Rosa Dr, Maricopa, AZ 85138-1835 Ph: (309) 299-0118 | Carlos Velazquez, 17212 N Rosa Dr, Maricopa, AZ 85138-1835 Ph: (309) 299-0118 |
News Archive
Combating malaria and other so-called vector diseases with chemical controls is increasingly ineffective, besides being hazardous for humans and the environment. These chemical controls must therefore be eliminated. In order to combat the diseases that insects and ticks transmit, all possible strategies must be united.
The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.
Researchers at the Case Western Reserve University School of Medicine, with colleagues from the John P. Hussman Institute for Human Genomics at the University of Miami, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, at Columbia University, and Wake Forest University School of Medicine will study the genomics of Alzheimer's disease (AD) in people with African heritage throughout the United States.
CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.
Researchers at the University of Wisconsin-Madison have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2) triggers robust immune responses to epitopes across the full viral proteome.
› Verified 2 days ago